|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
CausalMutation
|
CLINVAR |
|
|
|
|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Stomach Carcinoma
|
|
0.700 |
GeneticVariation
|
UNIPROT |
|
|
|
|
RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Breast adenocarcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.
|
2278970 |
1990 |
|
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
|
3122217 |
1987 |
|
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03).
|
15294875 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
|
Hypoglycemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
|
16361624 |
2005 |
|
Leukemia, Myelocytic, Acute
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Implications of NRAS mutations in AML: a study of 2502 patients.
|
16434492 |
2006 |
|
Malignant tumor of colon
|
|
0.050 |
GeneticVariation
|
BEFREE |
The GR/RR IRS1 genotypes were associated with an increased risk of colon cancers with the KRAS2 G12D mutation (OR 2.3, 95% CI 1.5, 3.5 versus controls, OR 1.7, 95% CI 1.1, 2.6 versus KRAS2 wild type), the "no 192" IGFI genotype increased the risk of the KRAS2 G13D mutation (OR 2.3, 95% CI 1.2, 4.2 versus controls, OR 2.1, 95% CI 1.1, 4.0 versus wild type), and the DD IRS2 genotype increased the risk of the G12V KRAS2 mutation (OR 1.8, 95% CI 0.9, 3.5 versus controls, OR 2.0, 95% CI 1.0, 4.0 versus wild type).
|
16448675 |
2006 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
|
16618717 |
2006 |
|
Thyroid Neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Autoimmune Lymphoproliferative Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
Hematologic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
Colorectal Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |
|
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
|
18316791 |
2008 |